PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG Plc Annual General Meeting and Interim Management Statement - BTG Plc (LSE: BGC), the specialist healthcare company, today holds its Annual General Meeting (AGM) and announces its interim management statement for the period from 1 April 2011 to 19 July - BTCplc.com
BTG Plc Annual General Meeting and Interim Management Statement

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/07/20 - BTG Plc (LSE: BGC), the specialist healthcare company, today holds its Annual General Meeting (AGM) and announces its interim management statement for the period from 1 April 2011 to 19 July - BTCplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The following summarises comments to be made by Dr John Brown, Chairman, and Louise Makin, CEO, at the Company’s AGM, which takes place at 10.30am today.

Trading has been in line with our expectations and the Company has made good commercial and clinical progress during the period.

In the specialty pharmaceuticals focus area, the US acute care sales team is performing well and sales of the antidote products CroFab® (crotalidae polyvalent immune fab (ovine)) and DigiFab® (digoxin immune fab (ovine)) are on budget.

On 6 July 2011, BTG announced the acquisition of US commercial rights to Wellstat Therapeutics Corporation’s product candidate uridine triacetate for use as a treatment for accidental overexposure to the chemotherapeutic 5-fluorouracil (5-FU). This product candidate is an excellent fit with BTG’s existing acute care business. A New Drug Application (NDA) is anticipated in the US in H1 2013, with the product continuing to be available to patients under emergency use INDs and an expanded access protocol in the intervening period.

On 14 July 2011, BTG received notification from the UK’s Medicines and Healthcare products Regulatory Agency that it has granted a Marketing Authorisation for DigiFab®, a treatment for patients with life-threatening digoxin toxicity or overdose. The product is already approved in the US, Canada and Switzerland.

BTG notified the US Food and Drug Administration (FDA) on 18 July 2011 that it had submitted the final components of the rolling Biologics License Application for Voraxaze® (glucarpidase), an experimental treatment for the rapid and sustained reduction of toxic methotrexate levels due to impaired renal function.

Within the interventional medicine focus area, recruitment has commenced for the team of medical science liaisons and account managers to support direct sales of LC Bead™ in the US from January 2012.

Varisolve® (polidocanol endovenous microfoam), under development as a novel treatment for varicose veins, continues to make good progress in its US phase III trials. Two studies are fully recruited: study VV017, which is designed to support an application for use following heat ablation of the great saphenous vein (GSV) to treat vein segments not treated by the ablation procedure, and VANISH-2 (study VV016), one of two pivotal studies intended to support a US regulatory application for approval as a single agent to treat the symptoms and appearance of varicose veins in people with incompetence of the GSV. VANISH-1 (study VV015), the second pivotal study, has now recruited over 50% of patients. All studies are on schedule for completion by the end of 2011, with data anticipated in H1 2012 and an NDA submission in H2 2012.

In the licensing and biotechnology area, treatment of patients with relapsing-remitting multiple sclerosis is nearing completion in the six month double-blind part of the Phase IIa study of BGC20-0134 (Pleneva™). Database lock is expected in Q3 2011 with additional data to follow from a six month open label study extension.

Among partnered programmes, Sanofi and its subsidiary Genzyme announced in July 2011 positive top-line results from the first of two Phase III studies comparing the use of alemtuzumab (Lemtrada™) with Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis. There was a 55% reduction in relapse rate compared to Rebif® over the two years of the study. Top-line results from the second pivotal Phase III study are expected in Q4 2011.

In May 2011, Centocor Ortho Biotech Inc. announced that the FDA had approved ZYTIGA™ (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. BTG received an undisclosed milestone payment following US approval and will receive a royalty on worldwide sales.

AstraZeneca’s Phase IIb study of AZD9773 (CytoFab™) is continuing to recruit patients with severe sepsis and/or septic shock, with data anticipated in H1 2012.

Louise Makin, chief executive officer of BTG, commented: “We are making good progress against our key priorities for the year and in executing our strategy. Our US acute care sales team is performing well and we are now recruiting a new interventional medicine team to support direct sales of the LC Bead™ in the US from January 2012. We anticipate further clinical progress in both our own and our partnered pipelines during the coming year, with data expected from Pleneva™, Varisolve®, Lemtrada™ and CytoFab™.”

For further information contact:

BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer
+44 (0)20 7575 0000

Financial Dynamics
Ben Atwell
+44 (0)20 7831 3113

About BTG
BTG (btgplc.com) is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG Plc Annual General Meeting and Interim Management Statement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG Plc |
Publisher Contact: Ashley Tapp - BTGplc.com 
+44(0)20 7575 1513 media[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)